Goldman Sachs has just slapped buy ratings on these ASX healthcare shares

These healthcare shares could offer sizeable returns according to one broker.

If you're wanting exposure to the healthcare sector, then it could be worth listening to what Goldman Sachs is recommending at this side of the market.

It has been looking at the services side of the sector and has picked out two ASX healthcare shares as buys.

The two companies in question are Capitol Health Ltd (ASX: CAJ) and Integral Diagnostics Ltd (ASX: IDX), which the broker notes provide exposure to structural growth in radiology at attractive valuations.

In respect to valuations, Goldman highlights:

Lowest growth-adjusted valuations across our coverage. We forecast 3Y EBITDA CAGRs (FY23-26E) of 12%/16% for CAJ/IDX respectively (vs ANZ HC coverage +12%). CAJ/IDX trade at growth adjusted multiples of 0.7x/ 0.6x, and screen as the mostly attractively valued across our coverage (1.9x).

Goldman also notes that the industry is highly fragmented, which provides consolidation opportunities. This could see both companies become either acquirers or takeover targets. It adds:

Long-term outperformers are those with leading operating efficiency and capital deployment strategies. A fragmented industry (top 6 players account for c.57% of market) provides opportunities for consolidation (given the scale benefits and potential revenue/cost synergies) as both an acquirer and target.

A doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

Strong returns on offer with these ASX healthcare shares

Now let's see what returns Goldman thinks could be on offer with these ASX healthcare shares.

For Capital Health, the broker has initiated coverage with a buy rating and 33 cents price target on its shares. This implies potential upside of 18% from current levels. Goldman is also forecasting a 3.7% dividend yield in FY 2024. Goldman adds:

CAJ is the sixth largest player in a structurally attractive industry and is a low cost community-based provider of radiology (underpins stable and defensive cash flows that are 77% government backed). A healthy balance sheet provides flexibility, and we believe its 7x NTM EBITDA multiple is attractive on a growth-adjusted basis (and relative to recent transaction multiples at c.13-14x).

As for Integral Diagnostics, its analysts have a buy rating and $3.70 price target on its shares. This suggests potential upside of 14% for investors. It also expects a 3.4% dividend yield in FY 2024. The broker adds:

We believe the market is under-appreciating the recovery in margins given our positive outlook on price/mix tailwinds/cost discipline. We forecast EBITDA margins of 20% in FY23E, recovering to 25% by FY26 (+180bps above consensus). IDX trades on 9x NTM EBITDA, vs our forecast 16% 3Y CAGR (most attractive vs coverage 21x/12%).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »